This is right.
In addition to their J&J recommendation, the panel also looked at whether mixing supplements from different manufacturers could improve protection against the virus. Their recommendations still have to be approved by the FDA and CDC.
We figure it out with two people.
Dr. Celine Gounder is an infectious disease specialist and epidemiologist at New York University’s Grossman School of Medicine, and she cares for patients at Bellevue Hospital Center. and Dr. Ashish Jha, dean of Brown University’s School of Public Health.
Good evening to you both. Many thanks to you both for coming here.
Dr. Gounder, you first.
Therefore, this advisory panel recommends this booster, the second dose of the Johnson & Johnson vaccine, for all adults 18 years of age and older.
By the way, we should also say that Johnson & Johnson is a funder of “Newshour”.
But during the testimony today the company kind of crumbled. There were questions about his data. One panelist suggests it should have been a two-dose vaccine.
All of that said, do you think the evidence for this booster is worthy?
Dr. Celine Gounder, infectious disease and public health specialist,: Look, I think it was noble to try a single-dose vaccine, I think, from an operation logistics standpoint, to vaccinate people, from an equity standpoint, that This means only one appointment, work leave, child care associated with it.
And I think many of us expected it to really stand the test of time. But what we’ve seen over time is that Johnson & Johnson Vaccine does not perform as well as Pfizer and Moderna Vaccine with respect to more significant outcomes, specifically, serious illness, hospitalization and death, not only Regarding the success transition. .
And what we’re seeing is that, with an extra dose of the vaccine, you actually get a boost of immunity with the Johnson & Johnson vaccine.